Abstract
The relationship between caveolin-1 (Cav-1) and clinicopathological characteristics of gastric cancer is controversial, although Cav-1 plays an important role in tumor metastasis. To evaluate the clinicopathological and prognostic value of expression in patients with gastric cancer, a meta-analysis was performed to investigate the impact on clinicopathological parameters and prognosis in gastric cancer cases. Studies assessing these parameters for Cav-1 in gastric cancer were identified up to June 2014. Finally, a total of six studies met the inclusion criteria. Our combined results showed that Cav-1 expression was significantly associated with the Lauren classification (pooled OR=0.603, 95% CI: 0.381-0.953, P=0.030). Furthermore, we found that Cav-1 expression predicted a better overall survival in gastric cancer patients (pooled OR=0.590, 95% CI: 0.360-0.970, P=0.038, fixed-effect). In conclusion, the overall data of the present meta analysis showed that Cav-1 expression was not correlated with clinicopathological features except for the Lauren classification. Simultaneously, Cav-1 overexpression predicted a better overall survival in gastric cancer. Cav-1 expression in tumors is a candidate positive prognostic biomarker for gastric cancer patients.
Highlights
Gastric cancer is one of the most common malignancies and remains the second leading cause of cancer related mortality worldwide (Li et al, 2012)
We found that Cav-1 expression predicted a better overall survival in gastric cancer patients
Even if it may play a role of tumor suppressor by inhibiting the signalling transduction products of some proto-oncogenes (Razani et al, 2001), its tyrosine-14 phosphorylation leads to growth stimulation (Lee et al, 2000), demonstrating that Cav-1 may make an effect as a pro-tumorigenic factor
Summary
Gastric cancer is one of the most common malignancies and remains the second leading cause of cancer related mortality worldwide (Li et al, 2012). Despite recent advances in medical treatment and surgical techniques, the five-year survival rate for gastric cancer patients remains poor. Caveolin-1 (Cav-1) is mainly expressed by adipocytes, fibroblasts, and endothelial and smooth muscle cells (Scherer et al, 1997). It is involved in signal transduction and transmembrane transport processes (Anderson et al, 1992). Cav amplification is frequently down-regulated in gastric cancer and is associated with better prognosis (He et al, 2012), but recently studies show that high Cav-1 levels predict poor outcome in gastric cancer (Nam et al, 2013)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
